This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matthaei, S. Articles by Häring, H.-U. Search for Related Content PubMed PubMed Citation Articles by Matthaei, S. Articles by Häring, H.-U.

Pathophysiology and Pharmacological Treatment of Insulin Resistance¹

Department of Internal Medicine IV (Endocrinology, Metabolism, Angiology, Pathobiochemistry and Clinical Chemistry), University of Tübingen, D-72076 Tübingen, Germany

Diabetes mellitus type 2 is a world-wide growing health problem affecting more than 150 million people at the beginning of the new millennium. It is believed that this number will double in the next 25 yr. The pathophysiological hallmarks of type 2 diabetes mellitus consist of insulin resistance, pancreatic ß-cell dysfunction, and increased endogenous glucose production. To reduce the marked increase of cardiovascular mortality of type 2 diabetic subjects, optimal treatment aims at normalization of body weight, glycemia, blood pressure, and lipidemia. This review focuses on the pathophysiology and molecular pathogenesis of insulin resistance and on the capability of antihyperglycemic pharmacological agents to treat insulin resistance, i.e., -glucosidase inhibitors, biguanides, thiazolidinediones, sulfonylureas, and insulin. Finally, a rational treatment approach is proposed based on the dynamic pathophysiological abnormalities of this highly heterogeneous and progressive disease.

This article has been cited by other articles:

				H. Staiger, F. Machicao, A. Fritsche, and H.-U. Haring Pathomechanisms of Type 2 Diabetes Genes Endocr. Rev., October 1, 2009; 30(6): 557 - 585. [Abstract] [Full Text] [PDF]

				G. E. Umpierrez, D. Smiley, G. Robalino, L. Peng, A. E. Kitabchi, B. Khan, A. Le, A. Quyyumi, V. Brown, and L. S. Phillips Intravenous Intralipid-Induced Blood Pressure Elevation and Endothelial Dysfunction in Obese African-Americans with Type 2 Diabetes J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 609 - 614. [Abstract] [Full Text] [PDF]

				S. M Nelson Obesity, insulin resistance and assisted conception The British Journal of Diabetes & Vascular Disease, January 1, 2009; 9(1): 23 - 26. [Abstract] [PDF]

				N. Stefan, K. Kantartzis, and H.-U. Haring Causes and Metabolic Consequences of Fatty Liver Endocr. Rev., December 1, 2008; 29(7): 939 - 960. [Abstract] [Full Text] [PDF]

				F. Chiarelli and M. L. Marcovecchio Insulin resistance and obesity in childhood Eur. J. Endocrinol., December 1, 2008; 159(suppl_1): S67 - S74. [Abstract] [Full Text] [PDF]

				C. X. Fang, F. Dong, D. P. Thomas, H. Ma, L. He, and J. Ren Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1206 - H1215. [Abstract] [Full Text] [PDF]

				K. Azuma, Z. Radikova, J. Mancino, F. G. S. Toledo, E. Thomas, C. Kangani, C. Dalla Man, C. Cobelli, J. J. Holst, C. F. Deacon, et al. Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 459 - 464. [Abstract] [Full Text] [PDF]

				J. Movassat, D. Bailbe, C. Lubrano-Berthelier, F. Picarel-Blanchot, E. Bertin, J. Mourot, and B. Portha Follow-up of GK rats during prediabetes highlights increased insulin action and fat deposition despite low insulin secretion Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E168 - E175. [Abstract] [Full Text] [PDF]

				F. Dong, Q. Li, N. Sreejayan, J. M. Nunn, and J. Ren Metallothionein Prevents High-Fat Diet Induced Cardiac Contractile Dysfunction: Role of Peroxisome Proliferator Activated Receptor {gamma} Coactivator 1{alpha} and Mitochondrial Biogenesis Diabetes, September 1, 2007; 56(9): 2201 - 2212. [Abstract] [Full Text] [PDF]

				J. J. Hernandez-Morante, F. Milagro, J. A. Gabaldon, J. A. Martinez, S. Zamora, and M. Garaulet Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans. Eur. J. Endocrinol., October 1, 2006; 155(4): 593 - 600. [Abstract] [Full Text] [PDF]

				B. Desvergne, L. Michalik, and W. Wahli Transcriptional Regulation of Metabolism Physiol Rev, April 1, 2006; 86(2): 465 - 514. [Abstract] [Full Text] [PDF]

				Y. Kawamura, Y. Tanaka, R. Kawamori, and S. Maeda Overexpression of Kruppel-Like Factor 7 Regulates Adipocytokine Gene Expressions in Human Adipocytes and Inhibits Glucose-Induced Insulin Secretion in Pancreatic {beta}-Cell Line Mol. Endocrinol., April 1, 2006; 20(4): 844 - 856. [Abstract] [Full Text] [PDF]

				X. C. Li, O. A. Carretero, Y. Shao, and J. L. Zhuo Glucagon Receptor-Mediated Extracellular Signal-Regulated Kinase 1/2 Phosphorylation in Rat Mesangial Cells: Role of Protein Kinase A and Phospholipase C Hypertension, March 1, 2006; 47(3): 580 - 585. [Abstract] [Full Text] [PDF]

				B. J Geesaman Genetics of aging: implications for drug discovery and development Am. J. Clinical Nutrition, February 1, 2006; 83(2): 466S - 469S. [Abstract] [Full Text] [PDF]

				T. Tang, J. Glanville, C. J. Hayden, D. White, J. H. Barth, and A. H. Balen Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study Hum. Reprod., January 1, 2006; 21(1): 80 - 89. [Abstract] [Full Text] [PDF]

				S. Kralisch, J. Klein, U. Lossner, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes J. Endocrinol., June 1, 2005; 185(3): R1 - R8. [Abstract] [Full Text] [PDF]

				S. Rice, N. Christoforidis, C. Gadd, D. Nikolaou, L. Seyani, A. Donaldson, R. Margara, K. Hardy, and S. Franks Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries Hum. Reprod., February 1, 2005; 20(2): 373 - 381. [Abstract] [Full Text] [PDF]

				G. Schernthaner, D. R. Matthews, B. Charbonnel, M. Hanefeld, P. Brunetti, and on Behalf of the Quarter Study Group Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6068 - 6076. [Abstract] [Full Text] [PDF]

				J. Klein, S. Westphal, D. Kraus, B. Meier, N. Perwitz, V. Ott, M. Fasshauer, and H H. Klein Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes J. Endocrinol., November 1, 2004; 183(2): 299 - 307. [Abstract] [Full Text] [PDF]

				R. Z. Lewanczuk, B. W. Paty, and E. L. Toth Comparison of the [13C]Glucose Breath Test to the Hyperinsulinemic-Euglycemic Clamp When Determining Insulin Resistance Diabetes Care, February 1, 2004; 27(2): 441 - 447. [Abstract] [Full Text] [PDF]

				V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF]

				M. Stumvoll, P. A. Tataranni, N. Stefan, B. Vozarova, and C. Bogardus Glucose Allostasis Diabetes, April 1, 2003; 52(4): 903 - 909. [Abstract] [Full Text] [PDF]

				J. E. Gunton, P. J. D. Delhanty, S.-I. Takahashi, and R. C. Baxter Metformin Rapidly Increases Insulin Receptor Activation in Human Liver and Signals Preferentially through Insulin-Receptor Substrate-2 J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1323 - 1332. [Abstract] [Full Text] [PDF]

				S. P. Marso Optimizing the diabetic formulary: beyond aspirin and insulin J. Am. Coll. Cardiol., August 21, 2002; 40(4): 652 - 661. [Abstract] [Full Text] [PDF]

				Y. Ido, D. Carling, and N. Ruderman Hyperglycemia-Induced Apoptosis in Human Umbilical Vein Endothelial Cells: Inhibition by the AMP-Activated Protein Kinase Activation Diabetes, January 1, 2002; 51(1): 159 - 167. [Abstract] [Full Text] [PDF]

				H. Cho, J. Mu, J. K. Kim, J. L. Thorvaldsen, Q. Chu, E. B. Crenshaw III, K. H. Kaestner, M. S. Bartolomei, G. I. Shulman, and M. J. Birnbaum Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBbeta ) Science, June 1, 2001; 292(5522): 1728 - 1731. [Abstract] [Full Text] [PDF]